Literature DB >> 20533605

Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery.

Susumu Hijioka1, Keisho Chin, Yasuyuki Seto, Noriko Yamamoto, Kiyohiko Hatake.   

Abstract

We report a case of advanced gastric cancer, with cervical, axillary, and abdominal paraaortic lymph node metastases, that was successfully treated with chemotherapy and surgery. The disease was initially considered unresectable, and the patient was treated with orally administered S-1. Chemotherapy was effective, and all lymph node metastases disappeared after 6 courses. After 27 mo of chemotherapy, the patient underwent curative surgery, with subtotal gastrectomy and lymph node dissection. Histopathological examination revealed many viable poorly differentiated adenocarcinoma cells in the stomach, but no cancer cells in the lymph nodes. The patient is alive, without recurrence, 8 years later. This, therefore, is a case report of an 8-year survivor of advanced gastric cancer with distant lymph node metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20533605      PMCID: PMC2883141          DOI: 10.3748/wjg.v16.i22.2824

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  12 in total

1.  Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.

Authors:  Motoki Yoshida; Atsushi Ohtsu; Narikazu Boku; Yoshinori Miyata; Kuniaki Shirao; Yasuhiro Shimada; Ichinosuke Hyodo; Wasaburo Koizumi; Minoru Kurihara; Shigeaki Yoshida; Seiichiro Yamamoto
Journal:  Jpn J Clin Oncol       Date:  2004-11       Impact factor: 3.019

2.  [A case of advanced gastric cancer with Virchow's and paraaortic lymph node metastases successfully resected after combined chemotherapy of low-dose CDDP and 5-FU].

Authors:  Y Wada; N Kamiya; S Asano; F Shinya
Journal:  Gan To Kagaku Ryoho       Date:  2001-01

3.  [A case of advanced gastric remnant carcinoma with Virchow's metastasis treated with neoadjuvant chemotherapy (low dose CDDP + 5-FU) followed by surgical resection].

Authors:  Y Umehara; T Okubo; Y Sano; R Sakamoto; T Nakamura; Y Tsuchiya; Y Nagato; R Moriyama
Journal:  Gan To Kagaku Ryoho       Date:  1995-02

4.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

5.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

Review 6.  Advances in the treatment of patients with gastric adenocarcinoma.

Authors:  Theodoros Foukakis; Lars Lundell; Michael Gubanski; Pehr A Lind
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

7.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Authors:  Narikazu Boku; Seiichiro Yamamoto; Haruhiko Fukuda; Kuniaki Shirao; Toshihiko Doi; Akira Sawaki; Wasaburo Koizumi; Hiroshi Saito; Kensei Yamaguchi; Hiroya Takiuchi; Junichiro Nasu; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2009-10-07       Impact factor: 41.316

8.  An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection.

Authors:  Takashi Iwazawa; Masakatsu Kinuta; Hiroshi Yano; Shigeo Matsui; Shinji Tamagaki; Atsushi Yasue; Kazuyuki Okada; Toshiyuki Kanoh; Takeshi Tono; Yoshiaki Nakano; Shigeru Okamoto; Takushi Monden
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

9.  The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up.

Authors:  M T Hallissey; J A Dunn; L C Ward; W H Allum
Journal:  Lancet       Date:  1994-05-28       Impact factor: 79.321

10.  Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

Authors:  Atsushi Ohtsu; Yasuhiro Shimada; Kuniaki Shirao; Narikazu Boku; Ichinosuke Hyodo; Hiroshi Saito; Noboru Yamamichi; Yoshinori Miyata; Nobumasa Ikeda; Seiichiro Yamamoto; Haruhiko Fukuda; Shigeaki Yoshida
Journal:  J Clin Oncol       Date:  2003-01-01       Impact factor: 44.544

View more
  3 in total

1.  Survival analysis of stage IV metastatic gastric cancer patients treated with HangAm-Plus.

Authors:  Jae-Woo Park; Jeungwon Yoon; Chong-Kwan Cho; Yeon-Weol Lee; Hwa-Seung Yoo
Journal:  Chin J Integr Med       Date:  2012-05-19       Impact factor: 1.978

2.  The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients.

Authors:  Long Yan; Hongbin Liu; Hongtao Li; Xiaopeng Han; Tingbao Cao; Chaoyang Wang; Gaitian Li
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  A fatal myelosuppression, diarrhea and neurotoxicity induced by combination of irinotecan and tegafur-gimeracil-oteracil potassium in the treatment of colon cancer: a case report.

Authors:  Yang-Xi Liu; Ke-Jia Le; Chi Zhang; Min Cui; Hong Zhou; Ying-Jie Su; Zhi-Chun Gu
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.